Latest & greatest articles for chronic kidney disease

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on chronic kidney disease or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on chronic kidney disease and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for chronic kidney disease

141. The double challenge of resistant hypertension and chronic kidney disease.

The double challenge of resistant hypertension and chronic kidney disease. Resistant hypertension is defined as blood pressure above goal despite adherence to a combination of at least three optimally dosed antihypertensive medications, one of which is a diuretic. Chronic kidney disease is the most frequent of several patient factors or comorbidities associated with resistant hypertension. The prevalence of resistant hypertension is increased in patients with chronic kidney disease, while (...) chronic kidney disease is associated with an impaired prognosis in patients with resistant hypertension. Recommended low-salt diet and triple antihypertensive drug regimens that include a diuretic, should be complemented by the sequential addition of other antihypertensive drugs. New therapeutic innovations for resistant hypertension, such as renal denervation and carotid barostimulation, are under investigation especially in patients with advanced chronic kidney disease. We discuss resistant

Lancet2015

142. Evaluation of Rhubarb Supplementation in Stages 3 and 4 of Chronic Kidney Disease: A Randomized Clinical Trial.

Evaluation of Rhubarb Supplementation in Stages 3 and 4 of Chronic Kidney Disease: A Randomized Clinical Trial. 26464863 2015 10 14 2015 10 14 2017 02 20 2356-6981 2014 2014 International journal of chronic diseases Int J Chronic Dis Evaluation of Rhubarb Supplementation in Stages 3 and 4 of Chronic Kidney Disease: A Randomized Clinical Trial. 789340 10.1155/2014/789340 Objective. To evaluate the efficacy and safety of Rhubarb supplementation in patients of chronic kidney disease. Material (...) and Methods. This study was a prospective comparative study conducted in patients of chronic kidney disease (stages 3 & 4) attending Renal Clinic of Department of Medicine, JN Medical College & Hospital, AMU, Aligarh. Patients were randomly divided into two interventional groups. Group I (Control) was given conservative management while Group II (Rhubarb) received conservative management along with Rhubarb capsule (350 mg, thrice daily) for 12 weeks. Haemogram and renal function tests were measured at 0

International journal of chronic diseases2015 Full Text: Link to full Text with Trip Pro

143. Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study.

Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study. BACKGROUND: Chronic hepatitis C virus (HCV) infection in patients with stage 4-5 chronic kidney disease increases the risk of death and renal graft failure, yet patients with hepatitis C and chronic kidney disease have few treatment options. This study assesses an all-oral, ribavirin (...) -free regimen in patients with HCV genotype 1 infection and stage 4-5 chronic kidney disease. METHODS: In this phase 3 randomised study of safety and observational study of efficacy, patients with HCV genotype 1 infection and chronic kidney disease (stage 4-5 with or without haemodialysis dependence) were randomly assigned to receive grazoprevir (100 mg, NS3/4A protease inhibitor) and elbasvir (50 mg, NS5A inhibitor; immediate treatment group) or placebo (deferred treatment group) once daily for 12

Lancet2015

144. A Positive Association Between Periodontal Disease and Chronic Kidney Disease is Evident, But Periodontal Treatment Effects Unknown

A Positive Association Between Periodontal Disease and Chronic Kidney Disease is Evident, But Periodontal Treatment Effects Unknown UTCAT2938, Found CAT view, CRITICALLY APPRAISED TOPICs University: | | ORAL HEALTH EVIDENCE-BASED PRACTICE PROGRAM View the CAT / Title A Positive Association Between Periodontal Disease and Chronic Kidney Disease is Evident, But Periodontal Treatment Effects Unknown Clinical Question In patients with chronic kidney disease, does periodontal treatment improve (...) kidney function (estimated glomerular filtration rate (eGFR))? Clinical Bottom Line Periodontal disease and chronic kidney disease share similar risk factors (smoking, impaired wound healing, diabetes mellitus, malnutrition, and poor oral hygiene) and a positive association between the two diseases has been shown. Intervention studies offer limited and inconsistent evidence for improvement following periodontal treatment in patients with CKD and periodontitis. No adverse outcomes were seen

UTHSCSA Dental School CAT Library2015

145. Guidelines for the Management of Chronic Kidney Disease (CKD)

Guidelines for the Management of Chronic Kidney Disease (CKD) 1 Northern Ireland Guidelines for the Management of Chronic Kidney Disease (CKD) Practical Points for Use of Estimated GFR and Albuminuria (ACR) in Assessing CKD Developed by GAIN and the Northern Ireland Nephrology Forum May 2015 2 Table of Contents Page Introduction 3-4 Methodology 5-7 What is CKD and eGFR (estimated Glomerular Filtration Rate)? 8-9 What causes CKD? 10 Who should I screen for CKD? 10 What baseline investigations (...) with a hospital referral 21 Patient involvement in CKD 21 Appendices Appendix 1 - Where can I get more information? 22 Appendix 2 - Contact Details 23 Appendix 3 - Management of chronic kidney disease: summary table 24 Appendix 4 - Abbreviations 25 Appendix 5 - Membership of GDG 26 3 Introduction Chronic kidney disease (CKD) is common, usually unrecognised and often exists in association with other conditions such as diabetes and cardiovascular disease. CKD is a general term covering a number of primary

Regulation and Quality Improvement Authority2015

146. Choice of Estimated Glomerular Filtration Rate Equation Impacts Drug-Dosing Recommendations and Risk Stratification in Patients With Chronic Kidney Disease Undergoing Percutaneous Coronary Interventions

Choice of Estimated Glomerular Filtration Rate Equation Impacts Drug-Dosing Recommendations and Risk Stratification in Patients With Chronic Kidney Disease Undergoing Percutaneous Coronary Interventions 26112195 2015 06 26 2015 09 10 2016 02 18 1558-3597 65 25 2015 Jun 30 Journal of the American College of Cardiology J. Am. Coll. Cardiol. Choice of Estimated Glomerular Filtration Rate Equation Impacts Drug-Dosing Recommendations and Risk Stratification in Patients With Chronic Kidney Disease (...) Undergoing Percutaneous Coronary Interventions. 2714-23 10.1016/j.jacc.2015.04.037 S0735-1097(15)02064-1 Multiple equations exist to estimate glomerular filtration rate (GFR); however, there is no consensus on which is superior for risk classification in patients with chronic kidney disease (CKD) undergoing percutaneous coronary intervention (PCI). The goals of this study were to identify which equation to estimate GFR is superior for predicting adverse outcomes after PCI and to examine how equation

EvidenceUpdates2015 Full Text: Link to full Text with Trip Pro

147. Chronic kidney disease.

Chronic kidney disease. This issue provides a clinical overview of chronic kidney disease, focusing on prevention, diagnosis, treatment, and patient information. The content of In the Clinic is drawn from the clinical information and education resources of the American College of Physicians (ACP), including ACP Smart Medicine and MKSAP (Medical Knowledge and Self-Assessment Program). Annals of Internal Medicine editors develop In the Clinic from these primary sources in collaboration

Annals of Internal Medicine2015 Full Text: Link to full Text with Trip Pro

148. Sucroferric oxyhydroxide (Velphoro) - For the control of serum phosphorus levels in adult chronic kidney disease (CKD) patients on haemodialysis (HD) or peritoneal dialysis (PD)

Sucroferric oxyhydroxide (Velphoro) - For the control of serum phosphorus levels in adult chronic kidney disease (CKD) patients on haemodialysis (HD) or peritoneal dialysis (PD)

Scottish Medicines Consortium2015

149. Erythropoiesis Stimulating Agents in Chronic Kidney Disease

Erythropoiesis Stimulating Agents in Chronic Kidney Disease Disclaimer: The Rapid Response Service is an information service for those involved in planning and providing health care in Canada. Rapid responses are based on a limited literature search and are not comprehensive, systematic reviews. The intent is to provide a list of sources of the best evidence on the topic that CADTH could identify using all reasonable efforts within the time allowed. Rapid responses should be considered along (...) . It may not be copied, posted on a web site, redistributed by email or stored on an electronic system without the prior written permission of CADTH or applicable copyright owner. Links: This report may contain links to other information available on the websites of third parties on the Internet. CADTH does not have control over the content of such sites. Use of third party sites is governed by the owners’ own terms and conditions. TITLE: Erythropoiesis Stimulating Agents in Chronic Kidney Disease

Canadian Agency for Drugs and Technologies in Health - Rapid Review2015

150. Dialysis in Stage 5 Chronic Kidney Disease

Dialysis in Stage 5 Chronic Kidney Disease Disclaimer: The Rapid Response Service is an information service for those involved in planning and providing health care in Canada. Rapid responses are based on a limited literature search and are not comprehensive, systematic reviews. The intent is to provide a list of sources of the best evidence on the topic that CADTH could identify using all reasonable efforts within the time allowed. Rapid responses should be considered along with other types (...) , posted on a web site, redistributed by email or stored on an electronic system without the prior written permission of CADTH or applicable copyright owner. Links: This report may contain links to other information available on the websites of third parties on the Internet. CADTH does not have control over the content of such sites. Use of third party sites is governed by the owners’ own terms and conditions. TITLE: Dialysis in Stage 5 Chronic Kidney Disease: Clinical Effectiveness and Guidelines DATE

Canadian Agency for Drugs and Technologies in Health - Rapid Review2015

151. Non-Steroidal Anti-Inflammatory Drugs in Patients with Hypertension, Chronic Kidney Disease, or Heart Failure

Non-Steroidal Anti-Inflammatory Drugs in Patients with Hypertension, Chronic Kidney Disease, or Heart Failure Disclaimer: The Rapid Response Service is an information service for those involved in planning and providing health care in Canada. Rapid responses are based on a limited literature search and are not comprehensive, systematic reviews. The intent is to provide a list of sources of the best evidence on the topic that CADTH could identify using all reasonable efforts within the time (...) -Inflammatory Drugs in Patients with Hypertension, Chronic Kidney Disease, or Heart Failure: Benefits, Harms, and Guidelines DATE: 10 March 2015 RESEARCH QUESTIONS 1. What are the clinical benefits and harms of using non-steroidal anti-inflammatory drugs (NSAIDS) in patients with hypertension, chronic kidney disease, or heart failure? 2. What are the evidence-based guidelines for using NSAIDS in patients with hypertension, chronic kidney disease, or heart failure? KEY FINDINGS One systematic review, one

Canadian Agency for Drugs and Technologies in Health - Rapid Review2015

152. Colestilan (BindRen) - treatment of hyperphosphataemia in adult patients with chronic kidney disease (CKD) stage 5 receiving haemodialysis or peritoneal dialysis

Colestilan (BindRen) - treatment of hyperphosphataemia in adult patients with chronic kidney disease (CKD) stage 5 receiving haemodialysis or peritoneal dialysis

Scottish Medicines Consortium2015

153. Qualitative?other: People with coexisting diabetes, chronic kidney disease and hypertension report the psychosocial effects of being prescribed multiple medications

Qualitative?other: People with coexisting diabetes, chronic kidney disease and hypertension report the psychosocial effects of being prescribed multiple medications People with coexisting diabetes, chronic kidney disease and hypertension report the psychosocial effects of being prescribed multiple medications | Evidence-Based Nursing This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts (...) OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here People with coexisting diabetes, chronic kidney disease and hypertension report the psychosocial effects of being prescribed multiple medications Article Text Adult nursing Qualitative—other People

Evidence-Based Nursing (Requires free registration)2015 Full Text: Link to full Text with Trip Pro

154. Chronic kidney disease: managing anaemia

Chronic kidney disease: managing anaemia Chronic kidne Chronic kidney disease: managing y disease: managing anaemia anaemia NICE guideline Published: 3 June 2015 nice.org.uk/guidance/ng8 © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When (...) with complying with those duties. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Chronic kidney disease: managing anaemia (NG8) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 45Contents Contents Overview 5 Who is it for? 5 Introduction 6

National Institute for Health and Clinical Excellence - Clinical Guidelines2015

155. Hyperphosphataemia in adults with chronic kidney disease on dialysis: sucroferric oxyhydroxide

Hyperphosphataemia in adults with chronic kidney disease on dialysis: sucroferric oxyhydroxide Hyperphosphataemia in adults with chronic kidney disease on dialysis: sucroferric oxyhydroxide | Guidance and guidelines | NICE Hyperphosphataemia in adults with chronic kidney disease on dialysis: sucroferric oxyhydroxide Evidence summary [ESNM51] Published date: January 2015 Share Save Advice Key points from the evidence Key points from the evidence The content of this evidence summary was up (...) -to-date in January 2015 . See (SPCs), (BNF) or the or websites for up-to-date information. Summary Sucroferric oxyhydroxide (Velphoro) is an iron‑based phosphate binder. In 1 open‑label, randomised controlled trial (RCT), sucroferric oxyhydroxide at a mean dose of 1500 mg iron (3 tablets) per day was non‑inferior to sevelamer carbonate at a mean dose of 6.4 g (8 tablets) per day for lowering phosphate levels in adults with chronic kidney disease (CKD) who were on haemodialysis or peritoneal dialysis

National Institute for Health and Clinical Excellence - Advice2015

156. Cohort study: Stricter systolic blood pressure control is associated with higher all-cause mortality in patients with chronic kidney disease

Cohort study: Stricter systolic blood pressure control is associated with higher all-cause mortality in patients with chronic kidney disease Stricter systolic blood pressure control is associated with higher all-cause mortality in patients with chronic kidney disease | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username (...) * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Stricter systolic blood pressure control is associated with higher all-cause mortality in patients with chronic kidney disease Article Text Prognosis Cohort study Stricter systolic blood pressure control is associated with higher all-cause

Evidence-Based Medicine (Requires free registration)2015 Full Text: Link to full Text with Trip Pro

157. Autosomal Dominant Polycystic Kidney Disease - Management of Chronic Pain

Autosomal Dominant Polycystic Kidney Disease - Management of Chronic Pain KHA-CARI Autosomal Dominant Kidney Disease Guideline: Management of Chronic Pain Judy Savige, MB BS, PhD, FRACP, *,† David J. Tunnicliffe, MIPH, ‡,§ and Gopala K. Rangan, MB BS, PhD, FRACP #,¶ GUIDELINERECOMMENDATIONS* a. We recommend that clinicians should include the eva- luation of pain in patients with autosomal dominant polycystic kidney disease during clinic visits (1D). b. We recommend that patients be involved (...) An initial assessment (detailed history, psychoso- cialassessment, and physicalexamination) should be performed to determine the most likely basis of chronic pain in patients with autosomal dominant polycystic kidney disease (ADPKD). The initial evaluation should attempt to distin- guish between acute pathology (often due to cyst infection, stones, or bleeding) and chronic pathol- ogy (caused by cyst expansion or mechanical back pain from increased kidney mass). Thus, pain due to cyst infection

KHA-CARI Guidelines2015

158. Pharmacotherapy in Chronic Kidney Disease Patients Presenting With Acute Coronary Syndrome

Pharmacotherapy in Chronic Kidney Disease Patients Presenting With Acute Coronary Syndrome Pharmacotherapy in Chronic Kidney Disease Patients Presenting With Acute Coronary Syndrome | Circulation Search for this keyword Search Search for this keyword Search Header Publisher Menu AHA Scientific Statement Pharmacotherapy in Chronic Kidney Disease Patients Presenting With Acute Coronary Syndrome A Scientific Statement From the American Heart Association Jeffrey B. Washam , Charles A. Herzog (...) .0000000000000183 Circulation. 2015; 131: 1123-1149 Originally published February 23, 2015 Jeffrey B. Washam Charles A. Herzog Amber L. Beitelshees Mauricio G. Cohen Timothy D. Henry Navin K. Kapur Jessica L. Mega Venu Menon Robert L. Page L. Kristin Newby Jump to Chronic kidney disease (CKD) is frequently encountered among patients presenting with acute coronary syndrome (ACS). Recent data from the National Cardiovascular Data Registry–Acute Coronary Treatment and Intervention Outcomes Network (NCDR-ACTION

American Heart Association2015 Full Text: Link to full Text with Trip Pro

159. Clinical Practice Guideline on management of patients with diabetes and chronic kidney disease stage 3b or higher (eGFR <45 mL/min)

Clinical Practice Guideline on management of patients with diabetes and chronic kidney disease stage 3b or higher (eGFR <45 mL/min) Clinical Practice Guideline on management of patients with diabetes and chronic kidney disease stage 3b or higher (eGFR <45 mL/min) | Nephrology Dialysis Transplantation | Oxford Academic We use cookies to enhance your experience on our website. By continuing to use our website, you are agreeing to our use of cookies. You can change your cookie settings at any time (...) . Search Account Menu Menu Navbar Search Filter Mobile Microsite Search Term Close search filter search input Article Navigation Close mobile search navigation Article navigation May 2015 Article Contents Article Navigation Clinical Practice Guideline on management of patients with diabetes and chronic kidney disease stage 3b or higher (eGFR <45 mL/min) Guideline development group Search for other works by this author on: Henk Bilo Search for other works by this author on: Luis Coentrão Search

European Renal Best Practice2015